E-Paper
Dr Reddy’s courts drug discovery
Pharmaceutical major Dr Reddy’s Laboratories (DRL) plans to drive future growth through introducing new drugs and differentiated formulations.
Pharmaceutical major Dr Reddy’s Laboratories (DRL) plans to drive future growth through introducing new drugs and differentiated formulations. The company is already researching the development of polypill, anti-cholesterol drug CETP
(cholesterol ester transfer protein) and biosimilars, among others.
“We want to be a company led by the discovery of drugs,” said Anji Reddy, chairman DRL.
The company has completed phase-I of the CETP trials and is entering phase-II, he said.
DRL’s vice-chairman and CEO, GV Prasad said the company would calibrate investments in proprietary products and other high risk R&D to establish financial stability.
“We believe the next wave of growth will come from proprietary products and would like to invest in developing these products,” said Prasad.
The company is eyeing a revenue of $3 billion (Rs 14,000 crore) by 2013. It posted a revenue of $1.37 billion (Rs 6,400 crore) in the last financial year.
